Patents by Inventor Hideki Horiuchi

Hideki Horiuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10994454
    Abstract: A thermally expandable sheet includes: a thermally expansive layer formed on a one surface of a base; a first ink receiving layer that is provided on the thermally expansive layer for receiving ink; a film provided on the first ink receiving layer; and a second ink receiving layer that is provided on the film for receiving ink; wherein the first ink receiving layer is formed of a material that provides a texture a different from a texture of the second ink receiving layer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 4, 2021
    Assignee: CASIO COMPUTER CO., LTD.
    Inventors: Yoshimune Motoyanagi, Yuji Horiuchi, Satoshi Mitsui, Hideki Takahashi
  • Patent number: 10793582
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Nobuaki Fujimoto
  • Publication number: 20190233438
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: October 21, 2016
    Publication date: August 1, 2019
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Nobuaki FUJIMOTO
  • Patent number: 10065972
    Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 4, 2018
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Noriaki Itagaki
  • Publication number: 20160376289
    Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: December 29, 2016
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Noriaki ITAGAKI
  • Publication number: 20160279106
    Abstract: The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Teijin Pharma Limited
    Inventors: Takanori UEDA, Takahiro YAMAUCHI, Mihoko MORITA, Hideki HORIUCHI
  • Publication number: 20150274680
    Abstract: The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: October 22, 2013
    Publication date: October 1, 2015
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Takanori Ueda, Takahiro Yamauchi, Mihoko Morita, Hideki Horiuchi
  • Patent number: 8877779
    Abstract: Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: November 4, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masakazu Nakano, Masanori Minoguchi, Tokushi Hanano, Shin-ichiro Ono, Hideki Horiuchi, Koji Teshima
  • Patent number: 8471032
    Abstract: The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. The present invention provides a crystal and a salt of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide in a crystal form.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: June 25, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumie Sekiguchi, Takayuki Ishige, Masanori Minoguchi, Hideki Horiuchi, Shinichirou Ono, Toshihiko Tanaka
  • Publication number: 20110178128
    Abstract: The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. The present invention provides a crystal and a salt of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide in a crystal form.
    Type: Application
    Filed: September 16, 2009
    Publication date: July 21, 2011
    Inventors: Sumie Sekiguchi, Takayuki Ishige, Masanori Minoguchi, Hideki Horiuchi, Shinichirou Ono, Toshihiko Tanaka
  • Publication number: 20110071044
    Abstract: According to one aspect, a microarray for nucleic acid detection includes a substrate, a negative control probe group immobilized on a first region of the substrate and provided with a plurality of first probes having different sequences, and a second probe immobilized on a second region of the substrate and containing a sequence complementary to a target nucleic acid.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 24, 2011
    Inventor: Hideki HORIUCHI
  • Patent number: 7910719
    Abstract: Provided is a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, includes a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: March 22, 2011
    Assignees: Kabushiki Kaisha Toshiba, Sekisui Medical Co., Ltd.
    Inventors: Koji Hashimoto, Keiko Ito, Naoko Nakamura, Hideki Horiuchi, Michie Hashimoto, Osamu Sato
  • Publication number: 20100120841
    Abstract: Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.
    Type: Application
    Filed: February 28, 2008
    Publication date: May 13, 2010
    Inventors: Masakazu Nakano, Masanori Minoguchi, Tokushi Hanano, Shin-ichiro Ono, Hideki Horiuchi, Koji Teshima
  • Publication number: 20090035750
    Abstract: Provided is a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, includes a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.
    Type: Application
    Filed: June 6, 2008
    Publication date: February 5, 2009
    Inventors: Koji Hashimoto, Keiko Ito, Naoko Nakamura, Hideki Horiuchi, Michie Hashimoto, Osamu Sato
  • Publication number: 20090023201
    Abstract: In a nucleic acid detecting cassette in which a heating treatment chamber and a liquid delivery channel are constituted of a stationary member and flexible members, the heating treatment chamber is held by convex heating sections from both sides, whereby the heat treatment chamber and the liquid delivery channel are spatially separated from each other. Thus, it is possible to automatically execute a consistent process including nucleic acid amplification and other required treatments of the object sample as well as detection of a target nucleic acid.
    Type: Application
    Filed: July 18, 2008
    Publication date: January 22, 2009
    Inventors: Sadato Hongo, Takahiro Kokubo, Hideki Horiuchi, Koji Hashimoto, Jun Okada
  • Patent number: 7390830
    Abstract: This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 ? and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain, as the active ingredient, cyclic amine derivatives represented by the following formula (I), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C1-C6 alkyl addition salts thereof.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: June 24, 2008
    Assignee: Teijin Limited
    Inventors: Tatsuki Shiota, Fuminori Miyagi, Takashi Kamimura, Tomohiro Ohta, Yasuhiro Takano, Hideki Horiuchi
  • Publication number: 20060099615
    Abstract: The present invention provides a method of preparing a detection target structure useful for detecting a target nucleotide sequence. For example, provided is a method of preparing a detection target structure from a target nucleic acid (1). The target nucleic acid includes a target nucleotide sequence 2 in a part. According to the method of the present invention, a nucleic acid is elongated by using a primer so as to permit the target nucleic acid to have a double strand structure in the portion other than the target nucleotide sequence 2, thereby affording a detection target structure 4. The present invention also provides the detection target structure thus prepared a detection method of the target nucleotide sequence by using the detection target structure, a kit for preparing the detection target structure, and an assay kit for detecting the target nucleotide sequence.
    Type: Application
    Filed: September 21, 2005
    Publication date: May 11, 2006
    Applicant: KABUSHIKI KAISHA TOSHIBA
    Inventors: Hideki Horiuchi, Koji Hashimoto
  • Patent number: 6455521
    Abstract: A condensed thiophene compound of the formula (I) wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof and hydrates thereof. The compound of the formula (I) of the present invention is useful as a novel antipsychotic agent which is effective for both positive symptoms and negative symptoms of schizophrenia, which is associated with less side effects such as extrapyramidal motor disorder and the like and which is less associated with serious side effects such as agranulocytosis and the like. In addition, this compound is also useful as a therapeutic agent of Alzheimer's disease and manic-depressive illness.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: September 24, 2002
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Koji Seio, Hiroshi Tanaka, Toshiyuki Kohara, Kenji Hashimoto, Masatake Fujimura, Hideki Horiuchi, Hiroshi Yasumatsu, Koreichi Kimura
  • Publication number: 20020042411
    Abstract: A condensed thiophene compound of the formula (I) 1
    Type: Application
    Filed: April 19, 2001
    Publication date: April 11, 2002
    Inventors: Koji Seio, Hiroshi Tanaka, Toshiyuki Kohara, Kenji Hashimoto, Masatake Fujimura, Hideki Horiuchi, Hiroshi Yasumatsu, Koreichi Kimura
  • Patent number: 6271225
    Abstract: A condensed thiophene compound of the formula (I) wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof and hydrates thereof. The compound of the formula (I) of the present invention is useful as a novel antipsychotic agent which is effective for both positive symptoms and negative symptoms of schizophrenia, which is associated with less side effects such as extrapyramidal motor disorder and the like and which is less associated with serious side effects such as agranulocytosis and the like. In addition, this compound is also useful as a therapeutic agent of Alzheimer's disease and manic-depressive illness.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: August 7, 2001
    Assignee: Welfide Corporation
    Inventors: Koji Seio, Hiroshi Tanaka, Toshiyuki Kohara, Kenji Hashimoto, Masatake Fujimura, Hideki Horiuchi, Hiroshi Yasumatsu, Koreichi Kimura